Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT06765070

Efficacy and Usability of the EXPLORER Exoskeleton in Children With Neurodevelopmental Disorders in Natural Environments

Neurodevelopmental disorders often lead to abnormal development of the Central Nervous System (CNS), frequently causing motor dysfunctions such as an inability to stand and walk. EXPLORER is a robotic gait exoskeleton designed to rehabilitate children with motor disabilities in home and outdoor environments.

The aim of this study is to evaluate the efficacy and usability of EXPLORER in children with motor disability within their natural settings, including home and community environments.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Age range

2 year–17 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Universidad Rey Juan Carlos, Alcorcón, Madrid, Spain

Loading trial locations.

About this study

Neurodevelopmental disorders often lead to abnormal development of the Central Nervous System (CNS), frequently causing motor dysfunctions such as an inability to stand and walk. Robotic devices are a useful tool in the rehabilitation of these children, but most of them are designed to be used in the clinical setting. EXPLORER is a robotic device designed to assist gait in children with motor disability in their homes and the community. The aim of this study is to evaluate the efficacy and usability of EXPLORER in children with motor disability within their natural settings, including home and community environments.

An initial session will be conducted in the participant's natural environment, during which the researchers will instruct the primary caregivers on the use of the device. Subsequently, the device will be left for a two-month period for use in the natural settings deemed appropriate by the family.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosis of any pathology or condition causing neurodevelopmental disorders.
  • Ability to continuously use the device for two weeks, at least 3 times per week, without causing excessive fatigue that would prevent the participant from carrying out their usual activities.
  • Availability and commitment from the family to use the device at least 3 times per week during the planned period, in different environments and with various objectives.
  • Medical authorization for standing, gait training and weight bearing.
  • Informed consent signed by legal guardians.
  • Maximum user weight of 60 kg.
  • Hip width (between greater trochanters) ≤37 cm.
  • Length of the thigh (distance from the greater trochanter to the lateral condyle of the tibia) from 21cm to 36cm.
  • Tibia leg length (distance from the lateral condyle of the tibia to the lateral malleolus) from 20cm to 35cm.
  • Shoe size ≤40 (EU)

Exclusion criteria

  • Medical contraindications for standing or walking.
  • Non-reducible contractures or heterotropic ossifications above the degrees allowed by the device or out of the trajectory imposed by the device
  • Spasticity equal to 4 on the Modified Ashworth Scale at the time of use of the device.
  • More than 20º of hip and/or knee non-reducible contractures at the time of using the exoskeleton.
  • Necessity to walk with more than 5º of hip abduction.
  • Impossibility to reach 5º of ankle dorsiflexion with ir without orthoses.
  • Lower length dysmetria that cannot be mitigated with a wedge under the foot.
  • Skin lesion on parts of the lower extremities that are in contact with the device.
  • History of fracture without trauma.
  • Presence of other conditions causing exercise intolerance (such as uncontrolled hypertension, coronary artery disease, arrhythmia, congestive heart failure, severe pulmonary disease).
  • Conductual disorders that may interfere with the use of the device or their participation in the study, like impulsiveness.
  • Allergy to any of the EXPLORER materials: cotton, nylon, polyester, PPS, PEEK or ABS.

Treatment and study plan

EXPLORER

Device

Two-week period with the robotics gait device for use in the natural settings deemed appropriate by the family.

Primary outcomes

  1. Serious Adverse Events

    Time frame: through study completion, along 2 weeks

    occurrence of any serious adverse event to the participant or the caregiver

  2. Falls prevalence

    Time frame: through study completion, along 2 weeks

    Number of falling events occurred from the participant or caregiver

  3. Skin integrity

    Time frame: through study completion, along 2 weeks

    Occurrence of any injury of the skin in the areas of contact and produced by the use of the device

  4. Pain (Visual Analogic Scale)

    Time frame: through study completion, along 2 weeks

    pain measured by the Visual Analogic Scale (VAS) by the participant and the caregiver, scored from 0 to 10, being 0 "no pain" and 10 "unbearable pain"

  5. Donning and doffing time

    Time frame: through study completion, along 2 weeks

    Time to don and doff the device to each participant

  6. Device usage time

    Time frame: through study completion, along 2 weeks

    Time using the device

  7. Number of steps

    Time frame: through study completion, along 2 weeks

    number of steps with the device

  8. Usage modes

    Time frame: through study completion, along 2 weeks

    two different usage modes (active and automatic).

  9. Speed

    Time frame: through study completion, along 2 weeks

    speed achieved with the device (steps per minute)

  10. Device accessibility

    Time frame: through study completion, along 2 weeks

    Environments where the device has been used and level of accessibility in each environment measured with a 5 points Likert scale (0 not accessible - 5 very accessible)

  11. Range of motion

    Time frame: Before starting the intervention (S1) and after completing the two weeks of use

    Passive Degree to which a joint can move (hip, knee, and ankle joints in both legs). From 0º to 180º.

  12. Participation

    Time frame: Before starting the intervention (S1) and after completing the two weeks of use

    Measured with the Child and Adolescent Scale of Participation. 20 ordinal scaled items across 4 subsections.

    Maximum total score is 80 (20 items x 4) and the minimum total score is 20 (20 items x 1)

Secondary outcomes

  1. QUEST

    Time frame: at the end of the intervention

    Using the Quebec User Evaluation of Satisfaction with Assistive Technology (QUEST 2.0) questionnaire administered to the participants' caregivers at the end of the intervention. The QUEST 2.0 scale has 12 items. Each item is rated on a 5-point Likert scale

Sponsors and collaborators

Lead sponsor

MarsiBionics

Industry

Collaborators

  • Hospital General Universitario Gregorio Marañon
  • Hospital Infantil Universitario Niño Jesús, Madrid, Spain
  • Hospital Universitario 12 de Octubre
  • Hospital Universitario La Paz
  • Universidad Rey Juan Carlos

Registry information

Official study title

Efficacy and Usability of the EXPLORER Exoskeleton in Children With Neurodevelopmental Disorders in Their Natural Environment

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Jan 9, 2025
Registry last updated
Sep 25, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.